Single-Pot Fabrication of Cellulose-Reinforced Solid Polymer Lithium-Ion Conductors

Flexible power sources are essential to enable the autonomous operation of portable electronic systems. Conventional liquid electrolytes are not desirable for flexible batteries because of safety concerns surrounding the use of flammable organic solvents. A polymer electrolyte presents a promising alternative due to its higher mechanical integrity and lower risk of leaking solvent. Though they have such advantages, these electrolytes have lower ionic conductivity compared to conventional liquid electrolytes and are typically prepared using multistep process sequences. Here, we demonstrate a “single-pot” synthetic approach that affords a flexible, free-standing solid polymer electrolyte comprising cellulose-based nanocrystals and a cross-linked interpenetrating polymer network. Polyethylene oxide (PEO) is blended with poly­(ethylene glycol) dimethacrylate (PEGDMA), cellulose nanocrystals, and a lithium salt to afford the cross-linked polymer electrolyte upon UV irradiation. The cross-linked PEGDMA matrix provides good mechanical properties, while PEO is known for excellent electrochemical stability and its ability to solubilize lithium salts. The nontoxic cellulose additive also contributes to good mechanical properties and serves as a reinforcing filler. Soft and flexible polymer electrolytes were prepared with this approach. When the cellulose nanocrystal content reached 10 wt % relative to the PEO fraction, ionic conductivity was retained at 20 °C compared to the PEO control. The results provide a path toward sustainable, polymer electrolytes with performance metrics suitable for applications having a lower energy demand

Additional file 4: of Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models

Effects of the anti-CTLA-4 immune checkpoint inhibitor antibody ipilimumab against MC1 PDXs implanted in hNSG mice. Once tumors reached ~ 150 mm3, animals were treated weekly with 10 mg/kg intravenous injections for up to 3 weeks; tumor volumes were evaluated twice weekly. The values represent the mean ± SEM (n = 8). (PPTX 50 kb

Additional file 1: of Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models

Representative figure showing the results of flow cytometric analysis of human cells collected from blood of nonhumanized and humanized NSG mice after 8, 16, and 22 weeks of intravenous injection of human CD34+ hematopoietic stem cells (HSCs). Procedures and antibodies used in these studies are described in the Methods section. (PPTX 722 kb

Additional file 5: of Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models

a Evaluation of the percentages of human CD45+ TILs present in MC1 PDX tumors engrafted in hNSG mice and collected from animals treated with either vehicle control or anti-PD-1 antibody. The values represent the mean ± SEM (n = 8). b Schematic representation of the method used to determine the cytotoxic activity of TILs by measuring the levels of the lactate dehydrogenase (LDH), a stable cytosolic enzyme that is released upon TIL-induced tumor cell lysis. TILs were isolated from MC1 PDX tumors engrafted in hNSG mice and treated with either vehicle or anti-PD1 antibody that were cocultured with disaggregated MC1 tumor cells obtained from the corresponding PDX grown in nonhumanized NSG mice. (PPTX 131 kb

Additional file 3: of Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models

IHC analysis of human CD4-, CD3-, CD8-, CD20-, CD68-, CD4-, and CD8-positive cells present in BCM-2147, MC1, and BCM-4913 tumor xenograft lung micrometastases. Representative IHC images of obtained using preparations of tumor samples grown in humanized NSG mice; 4× and 20× magnifications are shown counterstained with hematoxylin. (PPTX 3007 kb

Additional file 2: of Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models

Table S1 Analysis of HLA type in PDX BCM-2147/-4913 and CD34+ HSCs. HLA typing was performed by using PCR-SSO DNA-based procedures. The serological phenotype is an interpretation based on molecular typing data. ND Not determined. Table S2 Gene expression analysis (RNA-Seq) comparing MC1, BCM-2147, and BCM-4913 PDXs growing in nonhumanized vs. humanized NSG mice. Differentially expressed genes (DEGs) were selected by edge R-based p value and fold change (FC). Supplemental Methods. (DOCX 22 kb

Supplemental Figures 1-5 from Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer

Supplemental Figure 1. Docetaxel induce the expression of iNOS following a bell shape distribution, no consistent effect is observed on eNOS; Supplemental Figure 2. L-NMMA decreased iNOS and enhances docetaxel toxicity on MDA-MB 468; Supplemental Figure 3. Response to NOS inhibition therapy on TNBC PDXs. Supplemental Figure 4. (A) NOS inhibition mitigates pro-survival pathways activated by docetaxel; Supplemental Figure 5. NOS inhibition therapy enhance apoptotic response; Supplemental Figure 5. NOS inhibition therapy enhance apoptotic response.</p

Supplementary Table 2 from Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors

PDF file - 39K, Probability of DLT. This table estimates the probability of dose-limiting toxicity by dose level</p

Additional file 1 of Strategies to adapt and implement health system guidelines and recommendations: a scoping review

Additional file 1. Search strategy

Additional file 1 of Health system impacts of SARS-CoV − 2 variants of concern: a rapid review

Additional file 1